Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company’s web site at www.rosettagenomics.com.
- 17 years ago
QualityStocks
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Tags Rodman & Renshaw
Related Post
-
Building the Future of U.S. Mineral Independence: Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Highlights Vast Resource Potential at Alaska’s Ambler Mining District
Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include…
-
When Major Miners Pivot: What Hecla’s Nevada Renaissance Means for Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) and Adjacent Exploration Ground
Disseminated on behalf of Fairchild Gold Corp. (TSX.V: FAIR) (OTC: FCHDF) and may include paid advertising.…
-
Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Positioned for Platinum Supply Crunch
Disseminated on behalf of Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) and may…